vs

Side-by-side financial comparison of American Bitcoin Corp. (ABTC) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

American Bitcoin Corp. is the larger business by last-quarter revenue ($118.0M vs $70.6M, roughly 1.7× Viridian Therapeutics, Inc.\DE). On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 151.5%).

Bitcoin is the first decentralized cryptocurrency. Based on a free-market ideology, bitcoin was invented in 2008 when an unknown person published a white paper under the pseudonym of Satoshi Nakamoto. Use of bitcoin as a currency began in 2009, with the release of its open-source implementation. From 2021 to 2025, El Salvador adopted it as legal tender currency before revoking it. As bitcoin is pseudonymous, its use by criminals has attracted the attention of regulators, leading to its ban by...

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

ABTC vs VRDN — Head-to-Head

Bigger by revenue
ABTC
ABTC
1.7× larger
ABTC
$118.0M
$70.6M
VRDN
Growing faster (revenue YoY)
VRDN
VRDN
+81806.6% gap
VRDN
81958.1%
151.5%
ABTC

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ABTC
ABTC
VRDN
VRDN
Revenue
$118.0M
$70.6M
Net Profit
$-34.6M
Gross Margin
49.1%
Operating Margin
-192.8%
-56.7%
Net Margin
-49.0%
Revenue YoY
151.5%
81958.1%
Net Profit YoY
54.9%
EPS (diluted)
$-0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABTC
ABTC
VRDN
VRDN
Q4 25
$118.0M
Q3 25
$64.2M
$70.6M
Q2 25
$1.4M
Q1 25
$1.6M
Q4 24
$46.9M
Q3 24
$11.6M
Q2 24
$5.5M
Q1 24
$7.5M
Net Profit
ABTC
ABTC
VRDN
VRDN
Q4 25
Q3 25
$3.5M
$-34.6M
Q2 25
$3.4M
Q1 25
$-100.6M
Q4 24
Q3 24
$-576.0K
Q2 24
$-61.1M
Q1 24
$230.4M
Gross Margin
ABTC
ABTC
VRDN
VRDN
Q4 25
49.1%
Q3 25
56.0%
Q2 25
Q1 25
Q4 24
57.9%
Q3 24
4.2%
Q2 24
31.0%
Q1 24
35.4%
Operating Margin
ABTC
ABTC
VRDN
VRDN
Q4 25
-192.8%
Q3 25
11.2%
-56.7%
Q2 25
-162.1%
Q1 25
-350.8%
Q4 24
Q3 24
-87.8%
Q2 24
-106.4%
Q1 24
-20.8%
Net Margin
ABTC
ABTC
VRDN
VRDN
Q4 25
Q3 25
5.4%
-49.0%
Q2 25
249.2%
Q1 25
-6458.5%
Q4 24
Q3 24
-5.0%
Q2 24
-1107.2%
Q1 24
3076.2%
EPS (diluted)
ABTC
ABTC
VRDN
VRDN
Q4 25
$-0.07
Q3 25
$0.06
Q2 25
$-0.07
Q1 25
$-0.09
Q4 24
$1.10
Q3 24
$-0.15
Q2 24
$-0.10
Q1 24
$-0.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABTC
ABTC
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$490.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$665.8M
$503.0M
Total Assets
$1.2B
$577.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABTC
ABTC
VRDN
VRDN
Q4 25
Q3 25
$490.9M
Q2 25
$750.0K
Q1 25
$367.0K
Q4 24
$850.0K
Q3 24
$478.0K
Q2 24
$1.4M
Q1 24
$1.9M
Stockholders' Equity
ABTC
ABTC
VRDN
VRDN
Q4 25
$665.8M
Q3 25
$575.5M
$503.0M
Q2 25
$339.7M
Q1 25
$115.8M
Q4 24
$1.0B
Q3 24
$697.5M
Q2 24
$614.3M
Q1 24
$696.8M
Total Assets
ABTC
ABTC
VRDN
VRDN
Q4 25
$1.2B
Q3 25
$1.2B
$577.1M
Q2 25
$6.2M
Q1 25
$9.0M
Q4 24
$1.1B
Q3 24
$7.5M
Q2 24
$11.4M
Q1 24
$17.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABTC
ABTC
VRDN
VRDN
Operating Cash FlowLast quarter
$-79.6M
$-84.6M
Free Cash FlowOCF − Capex
$-84.7M
FCF MarginFCF / Revenue
-120.1%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABTC
ABTC
VRDN
VRDN
Q4 25
$-79.6M
Q3 25
$-39.0M
$-84.6M
Q2 25
$-879.0K
Q1 25
$-3.2M
Q4 24
$-54.0M
Q3 24
$-76.8M
Q2 24
$201.0K
Q1 24
$-983.0K
Free Cash Flow
ABTC
ABTC
VRDN
VRDN
Q4 25
Q3 25
$-84.7M
Q2 25
$-1.4M
Q1 25
Q4 24
$-60.6M
Q3 24
$-79.3M
Q2 24
$-874.0K
Q1 24
FCF Margin
ABTC
ABTC
VRDN
VRDN
Q4 25
Q3 25
-120.1%
Q2 25
-104.4%
Q1 25
Q4 24
-129.2%
Q3 24
-683.2%
Q2 24
-15.8%
Q1 24
Capex Intensity
ABTC
ABTC
VRDN
VRDN
Q4 25
Q3 25
0.2%
Q2 25
40.5%
Q1 25
Q4 24
14.1%
Q3 24
21.6%
Q2 24
19.5%
Q1 24
Cash Conversion
ABTC
ABTC
VRDN
VRDN
Q4 25
Q3 25
-11.21×
Q2 25
-0.26×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons